DOCSLIB.ORG

Substrate Interactions with Human Ferrochelatase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Substrate Interactions with Human Ferrochelatase Substrate interactions with human ferrochelatase Amy Medlock, Larkin Swartz, Tamara A. Dailey, Harry A. Dailey, and William N. Lanzilotta* Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602 Edited by JoAnne Stubbe, Massachusetts Institute of Technology, Cambridge, MA, and approved December 20, 2006 (received for review July 21, 2006) Ferrochelatase, the terminal enzyme in heme biosynthesis, cata- antibody raised against N-methylmesoporphyrin (N-MeMP) IX lyzes the insertion of ferrous iron into protoporphyrin IX to form catalyzes the insertion of metal ions (14–17), the general hypothesis protoheme IX. Human ferrochelatase is a homodimeric, inner has been that N-alkyl porphyrins are transition-state analogs (18– mitochondrial membrane-associated enzyme that possesses an 20). The crystal structure of B. subtilis ferrochelatase with bound essential [2Fe-2S] cluster. In this work, we report the crystal N-MeMP has served as the basis of mechanistic models for ferro- structure of human ferrochelatase with the substrate protopor- chelatases (21). These models, as well as resonance Raman and phyrin IX bound as well as a higher resolution structure of the site-directed mutagenesis studies, assume that the N-MeMP ob- R115L variant without bound substrate. The data presented reveal served in the crystal structure is bound in the active site of that the porphyrin substrate is bound deep within an enclosed ferrochelatase in an orientation that is identical to the spatial pocket. When compared with the location of N-methylmesopor- orientation of the natural substrate/product (22–24). Additionally, phyrin in the Bacillus subtilis ferrochelatase, the porphyrin is it has been assumed that the 36° macrocycle distortion observed in rotated by Ϸ100° and is buried an additional 4.5 Å deeper within the N-MeMP-bound crystal structure represents a catalytic inter- the active site. The propionate groups of the substrate do not mediate that occurs during normal turnover. Data presented herein protrude into solvent and are bound in a manner similar to what provide evidence that these assumptions may not be valid. has been observed in uroporphyrinogen decarboxylase. Further- To provide insight into the interaction of the physiological more, in the substrate-bound form, the jaws of the active site substrate with ferrochelatase, we have determined the structure mouth are closed so that the porphyrin substrate is completely of human ferrochelatase with bound protoporphyrin IX. The engulfed in the pocket. These data provide insights that will aid in human ferrochelatase enzyme used in this investigation was an the determination of the mechanism for ferrochelatase. E343K variant that has a higher affinity for protoporphyrin IX in comparison to the wild-type enzyme. We have also collected heme biosynthesis ͉ protoporphyrin IX ͉ x-ray crystallography ͉ higher resolution data for the previously reported R115L variant metal insertion of human ferrochelatase (25) without bound substrate. The position of the substrate in the E343K variant is distinctly etallated tetrapyrroles are present in most organisms and different from the previously reported orientation of N-MeMP Mparticipate in essential biochemical processes that include in the B. subtilis ferrochelatase (21). In addition to the spatial photosynthesis, oxygen transport, drug metabolism, transcrip- orientation of substrate within the active site of human ferro- tional regulation, NO synthesis, and oxidative phosphorylation. chelatase, this work also shows that the substrate-bound form of Metallation of tetrapyrroles is catalyzed by a group of enzymes the enzyme possesses a ‘‘closed’’ active site conformation that is named chelatases. This group includes, but is not limited to, notably different from the structure of the inhibitor-bound magnesium chelatase, which is essential for chlorophyll produc- B. subtilis ferrochelatase or the structure of the human enzyme tion (1), and ferrochelatase, which is essential for heme produc- without substrate. In both of the latter cases, the active sites are tion (2). Because of the diverse functions of heme, the latter distinctly ‘‘open.’’ These observations provide insight into the enzyme plays a critical role in human health. Human genetic ferrochelatase mechanism of catalysis and inhibition. defects affecting this enzyme have been identified and result in Results the disease erythropoietic protoporphyria (3). Human ferroche- latase, with its [2Fe-2S] cluster (4, 5), represents the convergence General Description of the Overall Structure and Substrate Binding of tetrapyrrole synthesis with iron supply and must play a key role Sites. The crystals of the E343K variant of human ferrochelatase in overall body iron metabolism (6). belong to the triclinic space group P1 (see Table 1), whereas the Ferrochelatases from a variety of sources have been cloned, space group for the initial structure of human ferrochelatase expressed, and characterized to various extents (2, 4), but it is the (containing the amino acid substitution R115L) reported by Wu Bacillus subtilis and mammalian ferrochelatases that have been et al. (25) is orthorhombic (P212121). In the latter case, the studied most extensively. These two enzymes represent the broadest asymmetric unit contained a single biological dimer. The dif- diversity among ferrochelatases examined to date with Ͻ10% ferent crystal symmetry between the substrate-bound form and sequence identity. The B. subtilis protein is a water-soluble, mono- the free enzyme suggests that substantial conformational dif- meric protein with no cofactors (7), whereas the human enzyme is ferences exist between the two forms of the enzyme. Upon an inner mitochondrial membrane-associated homodimer with a phasing and refinement, it was revealed that the asymmetric unit [2Fe-2S] cluster in each subunit (8). Nevertheless, there is clear of the E343K variant of human ferrochelatase contains two structural similarity between these two enzymes. A comparison of the structures reveals a root-mean-square deviation of only 2.4 Å ␣ Author contributions: A.M. and W.N.L. designed research; A.M., L.S., T.A.D., and W.N.L. for the C atoms. The majority of the conserved residues are located performed research; A.M., L.S., and W.N.L. analyzed data; and H.A.D. and W.N.L. wrote the BIOCHEMISTRY in the active site pocket. paper. Since the initial work by DeMatteis’ group that identified and The authors declare no conflict of interest. characterized the ‘‘green pigment’’ in livers of 3,5-dicarbethoxy- This article is a PNAS direct submission. 1,4-dihydrocollidine-treated mice as N-methylprotoporphyrin, Abbreviation: N-MeMP, N-methylmesoporphyrin. there has been considerable interest in N-alkylporphyrins as inhib- Data deposition: The atomic coordinates for the R115L and E343K human ferrochelatase itors of ferrochelatase (9–12). Because of the tight binding com- structures have been deposited in the Protein Data Bank, www.pdb.org (PDB ID codes 2HRC petitive inhibition of ferrochelatase by N-methylprotoporphyrin and 2HRE, respectively). (13), the fact that nonenzymatic metal insertion into porphyrins is *To whom correspondence should be addressed. E-mail: [email protected]. facilitated by macrocycle distortion, and the observation that an © 2007 by The National Academy of Sciences of the USA www.pnas.org͞cgi͞doi͞10.1073͞pnas.0606144104 PNAS ͉ February 6, 2007 ͉ vol. 104 ͉ no. 6 ͉ 1789–1793 Downloaded by guest on September 23, 2021 Table 1. Data collection and refinement statistics R115L E343K Space group P212121 P1 Wavelength 0.98 1.54 Resolution range, Å 40.0–1.7 50.0–2.5 Unique observations 100,275 53,845 Completeness 99.6 (98.2)* 96.7 (93.5) † Rsym,% 0.08 (14.7) 0.08 (28.2) I/␴ 29.1 (5.8) 13.5 (3.4) Unit cell (a, b, c) 88.5, 92.9, 110.4 61.9, 88.3, 93.2 Protein atoms 5,782 11,564 Solvent atoms 601 338 Resolution limits 40.0–1.7 50.0–2.5 Rcryst,% 22.1 21.6 Fig. 2. Structural alignment of the substrate-bound (E343K) and substrate- Rfree,% 24.2 27.8 free (R115L) forms of human ferrochelatase. The substrate-free form of rmsd bonds, Å 0.006 0.008 human ferrochelatase is shown in green, and the substrate-bound form of rmsd angles, ° 1.21 1.61 human ferrochelatase is shown in magenta. Regions of significant movement average B factor, Å2 21.8 31.1 in the substrate-bound form have been highlighted in red for clarity and include residues 90–115, 302–313, and 349–361. The [2Fe-2S] clusters for the *Numbers in parentheses denote values for the outermost resolution shell. substrate-free and substrate-bound forms are shown in yellow and orange, † ϭ͚ ͚ Ϫ͗ ͘ ͚ ͗ ͘ Rsym hkl [ I(Ihkl,I Ihkl )]/ hkl,I Ihkl , where Ihkl is the intensity of an individual respectively. measurement of the reflection with indices hkl and ͗Ihkl͘ is the mean intensity of that reflection. variant possess [2Fe-2S] clusters, as was reported previously for human ferrochelatase. copies of the biological dimer (Fig. 1), for a total of four peptide Comparison of the R115L variant that lacks bound substrate monomers and six protoporphyrin IX molecules. This finding is with the substrate-bound (E343K variant) form reveals that the shown in Fig. 1, which highlights the relative positions of the four enzyme with porphyrin bound possesses a significantly more monomers, six porphyrin molecules, and two detergent mole- ‘‘closed’’ active site conformation. The overall difference be- cules, as well as the [2Fe-2S] clusters. The fact that substrate was tween these two conformations is illustrated in Fig. 2. There is observed in the electron density is of interest because substrate an average deviation of 3.5 Å between the R115L and E343K was not added during the expression, isolation, or crystallization variants for the backbone atoms of residues 90–115. Substantial of the E343K variant. One protoporphyrin molecule is found in differences in the torsion angles of the peptide backbone for the each of the four active sites, and two are located at a noncrys- substrate-bound structure in comparison with the substrate-free tallographic 2-fold axis.
Load more

Recommended publications
  • Allosteric Regulation in Drug Design
    Mini Review Curr Trends Biomedical Eng & Biosci Volume 4 Issue 1 - May 2017 Copyright © All rights are reserved by Ashfaq Ur Rehman DOI: 10.19080/CTBEB.2017.04.5555630 Allosteric regulation in drug design Ashfaq Ur Rehman1,2*, Shah Saud3, Nasir Ahmad4, Abdul Wadood2 and R Hamid5 1State Key Laboratory of Microbial Metabolism, Department of Bioinformatics and Biostatistics, China 2Department of Biochemistry, Abdul Wali Khan University Mardan, Pakistan 3Laboratory of Analytical Biochemistry and Bio separation, Shanghai Jiao Tong University, China 4Department of Chemistry, Islama College University Peshawar, Pakistan 5Department of Bioinformatics, Muhammad Ali Jinnah University Islamabad, Pakistan Submission: May 02, 2017; Published: May 23, 2017 *Corresponding author: Ashfaq Ur Rehman, State Key Laboratory of Microbial Metabolism, Department of Bioinformatics and Biostatistics, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China, Tel: ; Fax: 86-21-34204348; Email: Abstract mechanism, which are initiated through attachment of ligand or inhibitors with the protein or enzymes other than active (orthosteric) sites. ThisProtein mini review and enzymes involved play mechanism, significant types roles and in importancebiological processes of allosteric of all regulations living organisms; in drug theirdesign functions process. are regulated through allosteric Keywords: Allosteric, Activator: Drug design Introduction and ultimately cause disease. While various biological processes expressed the control at different points in life time of protein function is pivotal. As all the cell processes are under carful For the survival of all organisms the significance of protein included regulation of gene expression, translation into protein control and if not properly controls this leads to the abnormality through control of activity and at last degradation of protein [1].
    [Show full text]
  • Tyrosine Kinase – Role and Significance in Cancer
    Int. J. Med. Sci. 2004 1(2): 101-115 101 International Journal of Medical Sciences ISSN 1449-1907 www.medsci.org 2004 1(2):101-115 ©2004 Ivyspring International Publisher. All rights reserved Review Tyrosine kinase – Role and significance in Cancer Received: 2004.3.30 Accepted: 2004.5.15 Manash K. Paul and Anup K. Mukhopadhyay Published:2004.6.01 Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S Nagar, Mohali, Punjab, India-160062 Abstract Tyrosine kinases are important mediators of the signaling cascade, determining key roles in diverse biological processes like growth, differentiation, metabolism and apoptosis in response to external and internal stimuli. Recent advances have implicated the role of tyrosine kinases in the pathophysiology of cancer. Though their activity is tightly regulated in normal cells, they may acquire transforming functions due to mutation(s), overexpression and autocrine paracrine stimulation, leading to malignancy. Constitutive oncogenic activation in cancer cells can be blocked by selective tyrosine kinase inhibitors and thus considered as a promising approach for innovative genome based therapeutics. The modes of oncogenic activation and the different approaches for tyrosine kinase inhibition, like small molecule inhibitors, monoclonal antibodies, heat shock proteins, immunoconjugates, antisense and peptide drugs are reviewed in light of the important molecules. As angiogenesis is a major event in cancer growth and proliferation, tyrosine kinase inhibitors as a target for anti-angiogenesis can be aptly applied as a new mode of cancer therapy. The review concludes with a discussion on the application of modern techniques and knowledge of the kinome as means to gear up the tyrosine kinase drug discovery process.
    [Show full text]
  • DNA Breakpoint Assay Reveals a Majority of Gross Duplications Occur in Tandem Reducing VUS Classifications in Breast Cancer Predisposition Genes
    © American College of Medical Genetics and Genomics ARTICLE Corrected: Correction DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes Marcy E. Richardson, PhD1, Hansook Chong, PhD1, Wenbo Mu, MS1, Blair R. Conner, MS1, Vickie Hsuan, MS1, Sara Willett, MS1, Stephanie Lam, MS1, Pei Tsai, CGMBS, MB (ASCP)1, Tina Pesaran, MS, CGC1, Adam C. Chamberlin, PhD1, Min-Sun Park, PhD1, Phillip Gray, PhD1, Rachid Karam, MD, PhD1 and Aaron Elliott, PhD1 Purpose: Gross duplications are ambiguous in terms of clinical cohort, while the remainder have unknown tandem status. Among interpretation due to the limitations of the detection methods that the tandem gross duplications that were eligible for reclassification, cannot infer their context, namely, whether they occur in tandem or 95% of them were upgraded to pathogenic. are duplicated and inserted elsewhere in the genome. We Conclusion: DBA is a novel, high-throughput, NGS-based method investigated the proportion of gross duplications occurring in that informs the tandem status, and thereby the classification of, tandem in breast cancer predisposition genes with the intent of gross duplications. This method revealed that most gross duplica- informing their classifications. tions in the investigated genes occurred in tandem and resulted in a Methods: The DNA breakpoint assay (DBA) is a custom, paired- pathogenic classification, which helps to secure the necessary end, next-generation sequencing (NGS) method designed to treatment options for their carriers. capture and detect deep-intronic DNA breakpoints in gross duplications in BRCA1, BRCA2, ATM, CDH1, PALB2, and CHEK2. Genetics in Medicine (2019) 21:683–693; https://doi.org/10.1038/s41436- Results: DBA allowed us to ascertain breakpoints for 44 unique 018-0092-7 gross duplications from 147 probands.
    [Show full text]
  • Itraq-Based Quantitative Proteomics Analysis Reveals the Mechanism Underlying the Weakening of Carbon Metabolism in Chlorotic Tea Leaves
    Article iTRAQ-Based Quantitative Proteomics Analysis Reveals the Mechanism Underlying the Weakening of Carbon Metabolism in Chlorotic Tea Leaves Fang Dong 1,2, Yuanzhi Shi 1,2, Meiya Liu 1,2, Kai Fan 1,2, Qunfeng Zhang 1,2,* and Jianyun Ruan 1,2 1 Tea Research Institute, Chinese Academy of Agricultural Sciences, Hangzhou 310008, China; [email protected] (F.D.); [email protected] (Y.S.); [email protected] (M.L.); [email protected] (K.F.); [email protected] (J.R.) 2 Key Laboratory for Plant Biology and Resource Application of Tea, the Ministry of Agriculture, Hangzhou 310008, China * Correspondence: [email protected]; Tel.: +86-571-8527-0665 Received: 7 November 2018; Accepted: 5 December 2018; Published: 7 December 2018 Abstract: To uncover mechanism of highly weakened carbon metabolism in chlorotic tea (Camellia sinensis) plants, iTRAQ (isobaric tags for relative and absolute quantification)-based proteomic analyses were employed to study the differences in protein expression profiles in chlorophyll-deficient and normal green leaves in the tea plant cultivar “Huangjinya”. A total of 2110 proteins were identified in “Huangjinya”, and 173 proteins showed differential accumulations between the chlorotic and normal green leaves. Of these, 19 proteins were correlated with RNA expression levels, based on integrated analyses of the transcriptome and proteome. Moreover, the results of our analysis of differentially expressed proteins suggested that primary carbon metabolism (i.e., carbohydrate synthesis and transport) was inhibited in chlorotic tea leaves. The differentially expressed genes and proteins combined with photosynthetic phenotypic data indicated that 4-coumarate-CoA ligase (4CL) showed a major effect on repressing flavonoid metabolism, and abnormal developmental chloroplast inhibited the accumulation of chlorophyll and flavonoids because few carbon skeletons were provided as a result of a weakened primary carbon metabolism.
    [Show full text]
  • Integrated Computational Approaches and Tools for Allosteric Drug Discovery
    International Journal of Molecular Sciences Review Integrated Computational Approaches and Tools for Allosteric Drug Discovery Olivier Sheik Amamuddy 1 , Wayde Veldman 1 , Colleen Manyumwa 1 , Afrah Khairallah 1 , Steve Agajanian 2, Odeyemi Oluyemi 2, Gennady M. Verkhivker 2,3,* and Özlem Tastan Bishop 1,* 1 Research Unit in Bioinformatics (RUBi), Department of Biochemistry and Microbiology, Rhodes University, Grahamstown 6140, South Africa; [email protected] (O.S.A.); [email protected] (W.V.); [email protected] (C.M.); [email protected] (A.K.) 2 Graduate Program in Computational and Data Sciences, Keck Center for Science and Engineering, Schmid College of Science and Technology, Chapman University, One University Drive, Orange, CA 92866, USA; [email protected] (S.A.); [email protected] (O.O.) 3 Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA * Correspondence: [email protected] (G.M.V.); [email protected] (Ö.T.B.); Tel.: +714-516-4586 (G.M.V.); +27-46-603-8072 (Ö.T.B.) Received: 25 December 2019; Accepted: 21 January 2020; Published: 28 January 2020 Abstract: Understanding molecular mechanisms underlying the complexity of allosteric regulation in proteins has attracted considerable attention in drug discovery due to the benefits and versatility of allosteric modulators in providing desirable selectivity against protein targets while minimizing toxicity and other side effects. The proliferation of novel computational approaches for predicting ligand–protein interactions and binding using dynamic and network-centric perspectives has led to new insights into allosteric mechanisms and facilitated computer-based discovery of allosteric drugs. Although no absolute method of experimental and in silico allosteric drug/site discovery exists, current methods are still being improved.
    [Show full text]
  • Noncanonical Coproporphyrin-Dependent Bacterial Heme Biosynthesis Pathway That Does Not Use Protoporphyrin
    Noncanonical coproporphyrin-dependent bacterial heme biosynthesis pathway that does not use protoporphyrin Harry A. Daileya,b,c,1, Svetlana Gerdesd, Tamara A. Daileya,b,c, Joseph S. Burcha, and John D. Phillipse aBiomedical and Health Sciences Institute and Departments of bMicrobiology and cBiochemistry and Molecular Biology, University of Georgia, Athens, GA 30602; dMathematics and Computer Science Division, Argonne National Laboratory, Argonne, IL 60439; and eDivision of Hematology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84132 Edited by J. Clark Lagarias, University of California, Davis, CA, and approved January 12, 2015 (received for review August 25, 2014) It has been generally accepted that biosynthesis of protoheme of a “primitive” pathway in Desulfovibrio vulgaris (13). This path- (heme) uses a common set of core metabolic intermediates that way, named the “alternative heme biosynthesis” path (or ahb), has includes protoporphyrin. Herein, we show that the Actinobacteria now been characterized by Warren and coworkers (15) in sulfate- and Firmicutes (high-GC and low-GC Gram-positive bacteria) are reducing bacteria. In the ahb pathway, siroheme, synthesized unable to synthesize protoporphyrin. Instead, they oxidize copro- from uroporphyrinogen III, can be further metabolized by suc- porphyrinogen to coproporphyrin, insert ferrous iron to make Fe- cessive demethylation and decarboxylation to yield protoheme (14, coproporphyrin (coproheme), and then decarboxylate coproheme 15) (Fig. 1 and Fig. S1). A similar pathway exists for protoheme- to generate protoheme. This pathway is specified by three genes containing archaea (15, 16). named hemY, hemH, and hemQ. The analysis of 982 representa- Current gene annotations suggest that all enzymes for pro- tive prokaryotic genomes is consistent with this pathway being karyotic heme synthetic pathways are now identified.
    [Show full text]
  • Metabolism of the Stimulated Rat Spleen: I. Ferrochelatase Activity As an Index of Tissue Erythropoiesis
    Metabolism of the stimulated rat spleen: I. Ferrochelatase activity as an index of tissue erythropoiesis Abraham Mazur J Clin Invest. 1968;47(10):2230-2238. https://doi.org/10.1172/JCI105908. Assay of the enzyme ferrochelatase in marrow, liver, spleen, and red cells has been employed to assess the extent of erythropoietic stimulation in animals bearing the Walker 256 carcinosarcoma and in rats treated by administration of phenylhydrazine, cobalt chloride, human urinary erythropoietin, or chronic blood loss. In all instances, the spleen sustains the most marked increase of ferrochelatase activity, per gram of tissue. Spleen erythropoietic activity stimulation was confirmed by quantitative measurements in respiring slices of 59Fe and 14C incorporation into hemoglobin and ferritin. Increased spleen ferrochelatase activity in cobalt chloride-treated rats is prevented by actinomycin D, indicating that stimulated synthesis of the enzyme is associated with the metabolism of RNA. Find the latest version: https://jci.me/105908/pdf Metabolism of the Stimulated Rat Spleen I. FERROCHELATASE ACTIVITY AS AN INDEX OF TISSUE ERYTHROPOIESIS ABRAHAM MAZUR From The New York Blood Center, New York 10021 A B S TR A C T Assay of the enzyme ferrochelatase examination or the measurement of incorporation in marrow, liver, spleen, and red cells has been of injected 59Fe into the tissues (4). In addition, employed to assess the extent of erythropoietic other splenic cells (reticuloendothelial cells) may stimulation in animals bearing the Walker 256 car- hypertrophy, e.g., in response to phenylhydrazine cinosarcoma and in rats treated by administration administration (5). of phenylhydrazine, cobalt chloride, human urinary Because the entire spleen is readily available, erythropoietin, or chronic blood loss.
    [Show full text]
  • Tyrosine Kinases
    KEVANM SHOKAT MINIREVIEW Tyrosine kinases: modular signaling enzymes with tunable specificities Cytoplasmic tyrosine kinases are composed of modular domains; one (SHl) has catalytic activity, the other two (SH2 and SH3) do not. Kinase specificity is largely determined by the binding preferences of the SH2 domain. Attaching the SHl domain to a new SH2 domain, via protein-protein association or mutation, can thus dramatically change kinase function. Chemistry & Biology August 1995, 2:509-514 Protein kinases are one of the largest protein families identified, This is a result of the overlapping substrate identified to date; over 45 new members are identified specificities of many tyrosine kinases, which makes it each year. It is estimated that up to 4 % of vertebrate pro- difficult to dissect the individual signaling pathways by teins are protein kinases [l].The protein kinases are cate- scanning for unique target motifs [2]. gorized by their specificity for serineithreonine, tyrosine, or histidine residues. Protein tyrosine kinases account for The apparent promiscuity of individual tyrosine kinases roughly half of all kinases. They occur as membrane- is a result of their unique structural organization. bound receptors or cytoplasmic proteins and are involved Enzyme specificity is typically programmed by one in a wide variety of cellular functions, including cytokine binding site, which recognizes the substrate and also con- responses, antigen-dependent immune responses, cellular tains exquisitely oriented active-site functional groups transformation by RNA viruses, oncogenesis, regulation that help to lower the energy of the transition state for of the cell cycle, and modification of cell morphology the conversion of specific substrates to products.Tyrosine (Fig.
    [Show full text]
  • Structure and Evolution of Protein Allosteric Sites
    Structure and evolution of protein allosteric sites by Alejandro Panjkovich Thesis submitted to Universitat Aut`onoma de Barcelona in partial fulfillment of the requirements for the degree of Doctor of Philosophy Director - Prof. Xavier Daura Tesi Doctoral UAB/ANY 2013 Ph.D. Program - Protein Structure and Function Institut de Biotecnologia i Biomedicina caminante, no hay camino, se hace camino al andar Antonio Machado,1912 Acknowledgements First of all I would like to thank my supervisor and mentor Prof. Xavier Daura for his consistent support and trust in my work throughout these years. Xavi, I deeply appreciate the freedom you gave me to develop this project while you were still carefully aware of the small details. Working under your supervision has been a rich and fulfilling experience. Of course, thanks go as well to current and past members of our institute, especially Rita Rocha, Pau Marc Mu˜noz,Oscar Conchillo, Dr. Mart´ınIndarte, Dr. Mario Ferrer, Prof. Isidre Gibert, Dr. Roman Affentranger and Dr. Juan Cedano for their technical and sometimes philo- sophical assistance. Help from the administrative staff was also significant, I would like to thank in particular Eva, Alicia and Miguel who where always ready to help me in sorting out unexpected bureaucratic affairs. I would also like to thank Dr. Mallur Srivatasan Madhusudhan and his group (especially Kuan Pern Tan, Dr. Minh Nguyen and Binh Nguyen), and also Dr. Gloria Fuentes, Cassio Fernandes, Youssef Zaki, Thijs Kooi, Rama Iyer, Christine Low and many others at the Bioinformatics Institute BII - A∗STAR in Singapore for the many interesting discussions and support during my stage over there.
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • Some Biochemical Changes in Heme Synthesis in Iron Deficiency
    Indian J Physiol Pharmacol 2000; 44 (4): 491-494 SOME BIOCHEMICAL CHANGES IN HEME SYNTHESIS IN IRON DEFICIENCY D. C. SHARMA* AND RATI MATHUR Department of Biochemistry, S. M. S. Medical College, Jaipur - 302 004 (Received on January 18, 2000) Abstract: Some enzymes and intermediates of heme synthesis were determined in blood and urine of 26 women with severe iron deficiency anemia (IDA). Erythrocyte free protoporphyrin was almost doubled and delta-aminolevulinate dehydrase significantly raised. But urinary excretion of delta-aminolevulinic acid and reticulocyte ferrochelatase were significantly reduced in iron deficiency anemia. Hence these could serve as useful indices of iron deficiency and consequent anemia. Key words: iron deficiency anemia delta-aminolevulinate dehydrase protoporphyrin ferrochelatase delta-aminolevulinic acid INTRODUCTION iron incorporation at the level of ferrochelatase. However, this enzyme was Anemia is the chief manifestation of never measured in blood in IDA, despite iron deficiency. Several parameters are reports of its decrease in human leucocytes available for diagnosis of iron deficiency (3) and pig heart muscle (4). Therefore, we anemia (IDA). These include classical decided to estimate it. parameters, like, erythrocyte morphology, red cell indices, bone marrow iron, Another enzyme of heme biosynthesis-­ serum iron, iron binding capacity, delta aminolevulinate dehydrase (ALAD) has transferrin saturation, and more recent been studied in IDA in the past but the tests-erythrocyte protoporphyrin, serum reports were conflicting; ranging from ferritin, transferrin receptors (1) and zinc normal (5) to higher (6-8) or reduced (3). protoporphyrin (2). Similar contradiction was also seen in the reported excretion of delta-aminolevulinic Iron is known to affect synthesis of heme acid (ALA) in urine by iron deficient anemic and free protoporphyrin accumulates in persons in this study.
    [Show full text]
  • Supplementary Information
    Supplementary information (a) (b) Figure S1. Resistant (a) and sensitive (b) gene scores plotted against subsystems involved in cell regulation. The small circles represent the individual hits and the large circles represent the mean of each subsystem. Each individual score signifies the mean of 12 trials – three biological and four technical. The p-value was calculated as a two-tailed t-test and significance was determined using the Benjamini-Hochberg procedure; false discovery rate was selected to be 0.1. Plots constructed using Pathway Tools, Omics Dashboard. Figure S2. Connectivity map displaying the predicted functional associations between the silver-resistant gene hits; disconnected gene hits not shown. The thicknesses of the lines indicate the degree of confidence prediction for the given interaction, based on fusion, co-occurrence, experimental and co-expression data. Figure produced using STRING (version 10.5) and a medium confidence score (approximate probability) of 0.4. Figure S3. Connectivity map displaying the predicted functional associations between the silver-sensitive gene hits; disconnected gene hits not shown. The thicknesses of the lines indicate the degree of confidence prediction for the given interaction, based on fusion, co-occurrence, experimental and co-expression data. Figure produced using STRING (version 10.5) and a medium confidence score (approximate probability) of 0.4. Figure S4. Metabolic overview of the pathways in Escherichia coli. The pathways involved in silver-resistance are coloured according to respective normalized score. Each individual score represents the mean of 12 trials – three biological and four technical. Amino acid – upward pointing triangle, carbohydrate – square, proteins – diamond, purines – vertical ellipse, cofactor – downward pointing triangle, tRNA – tee, and other – circle.
    [Show full text]